Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 172 systematic review(s)/meta-analysis(es). ^[1-171]
• VTE (venous thromboembolism) Prophylaxis in Non-Major Orthopedic Surgery: Rivaroxaban showed no statistically significant difference in preventive effect against VTE compared to low-molecular-weight heparin (LMWH) (RR (relative risk) 0.80; 95% CI (confidence interval) 0.31 to 2.07).
• Coronary Artery Disease (CAD) Management: Low-dose rivaroxaban (2.5 mg) significantly decreased all-cause mortality (HR (hazard ratio) 0.88; 95% CI 0.81-0.95), myocardial infarction (HR 0.81; 95% CI 0.70-0.94), and stroke (HR 0.61; 95% CI 0.49-0.76) compared to aspirin alone.
• Atrial Fibrillation (AF) in End-Stage Kidney Disease (ESKD): Factor Xa inhibitors, including rivaroxaban, were associated with a lower risk of stroke or systemic embolism (SSE) compared to vitamin K antagonists (VKAs) (OR 0.37; 95% CI 0.15-0.93).
• Residual Risk in Atherosclerotic Cardiovascular Disease: Rivaroxaban combined with aspirin reduced cardiovascular events and ischemic stroke compared to aspirin alone (HR 0.76; 95% CI 0.66-0.86).
• There is no statistically significant difference in bleeding events when comparing rivaroxaban to low-molecular-weight heparin (LMWH) in non-major orthopedic surgery (RR 1.15; 95% CI 0.75 to 1.76).
• Low-dose rivaroxaban combined with aspirin significantly increased the risk of major bleeding compared to aspirin alone (HR 1.66; 95% CI 1.40-1.97).
• There were no significant differences in major bleeding incidents when comparing rivaroxaban to aspirin in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA).
• In patients with atrial fibrillation and end-stage kidney disease (ESKD), there was no significant difference in major bleeding events between factor Xa inhibitors and vitamin K antagonists (VKAs) (HR 0.87; 95% CI 0.62-1.22).
• In the context of isolated superficial vein thrombosis (iSVT), rivaroxaban demonstrated superior outcomes in preventing thrombotic complications compared to low-molecular-weight heparin (LMWH).